anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The research data is planned to be collected between January 2023 and November 2023. Data will be collected from elderly individuals from the community. After the elderly individuals who meet the appropriate criteria are informed about the research, their verbal and written consent will be obtained that they agree to participate in the research.

Experimental Group In order to collect the pre-test data of the experimental group, individuals who accept the study will be asked to fill in the Personal Information Form, Sleep Quality Scale and Berg Balance Scale. The forms will be collected after the individuals mark the options closest to them on the forms. It is planned to last approximately 25-30 minutes. It is planned to recommend lavender scent as a nursing intervention to improve sleep quality in individuals with irregular sleep and low sleep quality. Participants in the experimental group will be informed about the effects of lavender scent on sleep and will be given lavender pouches. They will be informed that they should put these lavender pouches in their pillows where they sleep every day and that they should sleep with the lavender pouch for the next month, and that they should not make any changes in their rooms or beds other than the lavender pouch. After the one-month lavender scent application of the experimental group is completed, the post-test data will be collected for the experimental group. After the individuals who gave the closest answer to themselves completed the forms, the post-test data will be collected and the data collection phase of the research will be completed.

Control Group The study will start by collecting the pre-test data of the control group. Individuals who agree to participate in the study will be asked to fill in the Personal Information Form, Sleep Quality Scale and Berg Balance Scale to collect pre-test data. The forms will be collected after the individuals mark the options closest to them on the forms. After collecting the pre-test data, no intervention will be made to the participants for one month. At the end of one month, the control group will be administered the post-test with the same data collection tools.
A vaccine is prepared by adding to a culture of bacteria the antibiotic patulin or the semicarbozone or thiosemicarbazone thereof, in a quantity sufficient to inhibit the bacteria without altering the antigen, and then allowing the culture to autolyse. The quantity of patulin per litre of medium for a bacterial concentration of 107 per c.c. is 2.9 patulin of 2.2g semicarbazone or 1.6g. thiocarbazone. The autolipate is shaken with 0.5 to 1 per cent hydrated alumina, the adsorbent separated and suspended in a pharmaceutically acceptable vehicle, e.g. distilled water or physiological saline.  The preparation of an antibrucellic anticyphoid vaccine is described.
Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy. Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine. Choice of therapy is based on investigator's discretion. Treatment used in label. Insulin glargine is titrated according treatment algorithm. Treatment may last up to 72 weeks.
The invention discloses a novel method for extracting pectin from sweet potato dregs. The method comprises the following steps of: 1) preparing the sweet potato dregs into a suspension, carrying out physical screening processing on the suspension, and removing most starch to obtain dietary fibers with higher purity; 2) using amylase to carry out enzymolysis on residual small amount of starch in the dietary fibers in step 1), carrying out centrifugation, removing supernate, and collecting sediments; and 3) preparing the sediments obtained in step 2) into the suspension, adding Na2HPO4 solution into the suspension to extract the pectin, carrying out centrifugation after extracting, collecting supernatant, and carrying out concentration and drying to obtain pectin powder. The method can make the extraction ratio of the sweet potato pectin reach 95.87 percent and the purity of pectin products reach 91.28 percent (taking Xu55-2 as a material). The method has the advantages of high extraction ratio, high pectin purity, strong practicality, easy industrialization and the like. The products can be directly used as food additives or pharmaceutical excipients. The method not only can improve the comprehensive economic benefit of potato processing, but also can reduce the environmental pollution caused by accumulation of the potato dregs.
The invention discloses a double-targeting gene line for accurate treatment of bladder cancer, and relates to the technical field of artificial gene application. The double-targeting gene comprises an A gene line and a B gene line, wherein the A gene line is shown as SEQ ID NO. 1, and the structure is as follows: an artificial promoter for monitoring the activity of the TGF-beta/Smad pathway, namely dCAS9-VPR, wherein the artificial promoter for monitoring the activity of the TGF-beta/Smad pathway is shown as SEQ ID NO. 2; the B gene line is shown as SEQ ID NO. 3, the structure of the B gene line is an artificial promoter-ribozyme-BAX-ribozyme for monitoring the activity of the MAPK/ERK pathway, and the artificial promoter for monitoring the activity of the MAPK/ERK pathway is shown as SEQ ID NO. 4. The invention realizes specific intervention on bladder cancer cells by reprogramming the oncogenic signal pathway of the cells, without affecting normal cells.
Liver fibrosis (LF) occurs when the liver tissue responds to injury or inflammation by producing excessive amounts of scar tissue, known as the extracellular matrix. This buildup stiffens the liver tissue, hinders blood flow, and ultimately impairs liver function. Various factors can trigger this process, including bloodborne pathogens, genetic predisposition, alcohol abuse, non-steroidal anti-inflammatory drugs, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease. While some existing small-molecule therapies offer limited benefits, there is a pressing need for more effective treatments that can truly cure LF. RNA therapeutics have emerged as a promising approach, as they can potentially downregulate cytokine levels in cells responsible for liver fibrosis. Researchers are actively exploring various RNA-based therapeutics, such as mRNA, siRNA, miRNA, lncRNA, and oligonucleotides, to assess their efficacy in animal models. Furthermore, targeted drug delivery systems hold immense potential in this field. By utilizing lipid nanoparticles, exosomes, nanocomplexes, micelles, and polymeric nanoparticles, researchers aim to deliver therapeutic agents directly to specific biomarkers or cytokines within the fibrotic liver, increasing their effectiveness and reducing side effects. In conclusion, this review highlights the complex nature of liver fibrosis, its underlying causes, and the promising potential of RNA-based therapeutics and targeted delivery systems. Continued research in these areas could lead to the development of more effective and personalized treatment options for LF patients.
The BIP is a psychoeducational intervention that will be delivered in 60- minute individual weekly sessions over 18 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including video vignettes and role plays to teach anger management skills.
Active LNAA tablets are given to each participant in 3 multiple crossovers for a total exposure to the Active Comparator 3 times. The allocation is randomized within each cycle of two treatments (active/inactive). There are 3 total cycles for each participant. The intervention is PreKUnil® tablets.
Cancer cachexia (CC) is a devastating condition affecting up to 80% of cancer patients, diminishing quality of life and contributing to increased mortality. Cancer cachexia is a complex metabolic syndrome characterized by the loss of skeletal muscle mass and weakness. The muscle pathology of cancer cachexia is not only related to muscle atrophy but also to disruptions to the contractile apparatus of the muscle. While physiologic disruptions in muscle sarcomere and myofiber membrane integrity have been observed despite the lack of injury, the totality of the muscle specific mechanisms contributing to these phenotypes have not been described, nor investigated in the context of pancreatic cancer (PC) where cachexia is a significant clinical problem. Therefore, delineating specific mechanisms of muscle catabolism in PC is critical to developing clinical therapies to control wasting and improve patient quality of life, clinical outcomes and long-term survival.

A variety of tumor promoting and inflammatory cell signaling pathways have been implicated in cancer cachexia, whereby pro-inflammatory cytokines have been implicated as a driving force. Remarkably, approximately half of all patients with PC demonstrate a measurable acute phase response, which is associated with poor clinical outcomes. Importantly, systemic elevations of these inflammatory mediators are due to a complex local interplay between the developing tumor and the immune system which subsequently leads to a systemic chronic inflammatory state. PC appears to manipulate the immune system to promote its survival at the expense of nutritional stores which results in cachexia. Therefore, understanding of the local and systemic inflammatory response in PC and its relation to muscle specific mechanisms is crucial to developing effective therapies for cancer cachexia.

PC associated cachexia results in a significant therapeutic dilemma. Local approaches such as surgery for curative intent encounter a high recurrence rate which is indicative of the systemic nature of even very early-stage disease. Therefore, systemic therapies are necessary for long-term survival. Unfortunately, effective chemotherapies are only offered to patients with good clinical parameters such as nutritional status. In other words, if the patient is too weak, they are not offered effective therapies for the risk of causing more harm than good.
An analysis and unusual event detection method is presented herein that was developed systematically for bio-intelligence in the area of syndromic surveillance using over-the-counter (OTC) pharmaceutical sales data. First, a measurement scheme was defined. It bases on historical sales records and a set of derived seasonally varying reference lines. The relative deviation (RD) of the current daily medicine sales data from the reference lines, the n-days cumulation of the relative deviations, and the daily change of the relative deviations are calculated. Second, a dynamic system model for categorized public health status was developed and described by a set of state variables and state transitions. State transitions are determined by a rule system. The combination of the quantitative measurements listed above establishes the supporting set for the rule system. Therefore, the dynamic change of public health status is systematically modeled over time and space by rule-system-driven state transitions. Certain system states represent unusual events and can be fully described through this methodology.
Early diagnosis of subcortical vascular mild cognitive impairment (svMCI) is clinically essential because it is the most reversible subtype of all cognitive impairments. Since structural alterations of hippocampal sub-regions have been well studied in neurodegenerative diseases with pathophysiological cognitive impairments, we were eager to determine whether there is a selective vulnerability of hippocampal sub-fields in patients with svMCI. Our study included 34 svMCI patients and 34 normal controls (NCs), with analysis of T1 images and Montreal Cognitive Assessment (MoCA) scores. Gray matter volume (GMV) of hippocampal sub-regions was quantified and compared between the groups, adjusting for age, sex, and education. Additionally, we explored correlations between altered GMV in hippocampal sub-fields and MoCA scores in svMCI patients. Patients with svMCI exhibited selectively reduced GMV in several left hippocampal sub-regions, such as the hippocampal tail, hippocampal fissure, CA1 head, ML-HP head, CA4 head, and CA3 head, as well as decreased GMV in the right hippocampal tail. Specifically, GMV in the left CA3 head was inversely correlated with MoCA scores in svMCI patients. Our findings indicate that the atrophy pattern of patients with svMCI was predominantly located in the left hippocampal sub-regions. The left CA3 might be a crucial area underlying the distinct pathophysiological mechanisms of cognitive impairments with subcortical vascular origins.
BACKGROUND AND AIMS: Myenteric plexitis is correlated with postoperative recurrence of Crohn's disease when relying on traditional statistical methods. However, comprehensive assessment of myenteric plexus remains challenging. This study aimed to develop and validate a deep learning system to predict postoperative recurrence through automatic screening and identification of features of the muscular layer and myenteric plexus.
METHODS: We retrospectively reviewed 205 patients who underwent bowel resection surgery from two hospitals. Patients were divided into a training cohort [n = 108], an internal validation cohort [n = 47], and an external validation cohort [n = 50]. A total of 190 960 patches from 278 whole-slide images of surgical specimens were analysed using the ResNet50 encoder, and 6144 features were extracted after transfer learning. We used five robust algorithms to construct classification models. The performances of the models were evaluated based on the area under the receiver operating characteristic curve [AUC] in three cohorts.
RESULTS: The stacking model achieved satisfactory accuracy in predicting postoperative recurrence of CD in the training cohort (AUC: 0.980; 95% confidence interval [CI] 0.960-0.999), internal validation cohort [AUC: 0.908; 95% CI 0.823-0.992], and external validation cohort [AUC: 0.868; 95% CI 0.761-0.975]. The accuracy for identifying the severity of myenteric plexitis was 0.833, 0.745, and 0.694 in the training, internal validation and external validation cohorts, respectively.
CONCLUSIONS: Our work initially established an interpretable stacking model based on features of the muscular layer and myenteric plexus extracted from histological images to identify the severity of myenteric plexitis and predict postoperative recurrence of CD.
The present invention relates to a chewable formulation for delivering a nutritional or pharmaceutically active agent to an animal target. The chewable formulation comprises a nutritional ingredient or an effective amount of a pharmaceutically active agent, and a 5 plasticiser. The chewable formulation is formed by extrusion and the formulation contains substantially no unbound water, nor is any water added in the manufacturing process. The present invention also relates to a method of manufacturing a shelf stable chewable formulation which comprises mixing the nutritional or pharmaceutically active agent with a fat, lipid or fat and lipid to obtain a first composition, adding one or more 0 plasticizers to the first mixture to obtain a second composition, extruding the second composition at a temperature sufficient to melt the fat and lipid, and allowing the extruded second composition to cool to room temperature thereby providing the chewable formulation. Nutritional ingredient, or Pharmaceutically active agent Optionally - a filler, diluent or filler and diluent, - a binder, | a sweetener, a flavouring agent, | a plasticizer, 2 a humectant, * a fat, lipid or fat and lipid, an antioxidant, -- --------- - - -- |- a colouring agent, - - a disintegrating agent, re- caoclourngtaent Pre-composition - a preservative, buffering agent, or preservative and buffering agent, 3 a lubricant, f, ld oa complexing agent, fat, lipid or fat and - a coating agent, .i-i- a surfactant, l a solubility enhancer, bioavailability enhancer, or a solubility enhancer and a + I bioavailability enhancer, a palatability enhancer, or First composition - a non-aqueous solvent or vehicle, or - any combination of any two or 5 more thereof. Optional plasticizer 4 ISecond composition 6 Extrusion Chewable _f 8 formulation Figure 1
First, all eligible patients will be screened for inclusion and exclusion and will be assigned to the experimental group and the control group. The experimental group will participate in a remote rehabilitation program via Lumosity platform, providing video-games aimed at strengthening specific cognitive functions for 30 minutes a day, 5 days a week, for a total of 8 weeks. The control group will watch a series of animated / TV shows, again for 30 minutes a day, 5 days a week, for 8 weeks. Once a week the patient (or his family) will be contacted by the researcher to check the progress of the treatment. All patients will be evaluated within a week before the start of treatment and after the end of treatment with a standardized neuropsychological assessment battery (NEPSY-II) designed to evaluate the effects of the treatment. Patients (or their parents according to participants' age) will also compile a questionnaire to assess behavioral problems (CBCL); a questionnaire for the assessment of cognitive functions in an ecological context (BRIEF-2); a quality of life questionnaire (TACQOL) and ad-hoc treatment appreciation questionnaire. In addition to the cognitive-behavioral assessment, specific parameters of cortical activity will be recorded (via EEG), in order to evaluate any changes in predefined neurophysiological markers able to reflect the effects of the treatment. Evidence gathered from the literature reports that the relationship between theta and beta waves (the so-called theta/beta ratio) may be considered an index of a behavioral adaptation deficit in populations with poor executive control. Therefore, this index appears to be the ideal candidate to detect changes in cortical activity which may underlay behavioral effects of home rehabilitation treatment. Thus, resting-state cortical activity will be recorded before and after the treatment.
FIELD: veterinary science. SUBSTANCE: the present method deals with treating dyspepsia in neonatal calves by introducing immunostimulating and antimicrobial preparations into animal's body. As immunostimulating preparation one should apply antihistaminic serum at titer of antibodies to histamine to be 1:256. Antihistaminic serum should be injected subcutaneously at the dosage of 10.0-15.0 ml/calf, once daily, thrice at 2-3 d interval. The suggested method enables to simplify therapy of inspecific dyspepsia in calves in early postnatal period. EFFECT: higher efficiency of therapy. 1 tbl
987,322. Dispensing liquids by gaseous pressure. AEROSOL-SERVICE A.G. March 22, 1963 [March 23, 1962], No. 11408/63. Heading F1R. [Also in Division B8] A process for filling a pressurized container with a self-atomizing or framing aerosol composition containing dissolved gas or gases comprises forming a solution, emulsion or suspension of a substance to be atomized or formed in a liquid which is a solvent for carbon dioxide or vitrous oxide, saturating said solution, emulsion or suspension with carbon dioxide, vitrous oxide or a mixture thereof under pressure in a pressure vessel, and charging the resulting saturated liquid into the container, either through its dispensing valve or between the valve and the container body, while maintaining the liquid under pressure. Examples are described for preparing cream, a toilet water and a mothicide.
Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...): A. Preoperative preparation: All patients will be subjected to evaluation including: 1. Measurement of penile length and width (in cm). 2. The shape of glans. (clefted , incomplete ceft, flat) 3. Glans size is measured by cubic centimetres. 4. Presence or absence of chordee and its degree. 5. Urethral plate condition and it's length, width and surface area. 6. Condition of skin over the urethra. 7. Presence of penile torsion. All patients should undergo preoperative surgical fitness including; complete blood picture, prothrombin time, concentration and INR, ECG and renal function test. Prophylactic systemic antibiotics are given intraoperatively.
Background: Non-communicable diseases (NCDs), such as cardiovascular diseases, are important global health concerns. Accurate dietary assessment is pivotal in understanding the relationship between food intake and health outcomes. Presently, there is a notable absence of a comprehensive dietary assessment tool tailored for the Turkish population.

Objective: The primary objective of this research is to adapt and validate the web-based eNutri Food Frequency Questionnaire (FFQ) and Diet Quality Score (DQS) for the Turkish population, addressing the current gap in dietary assessment methods.

Design and Proposed Analysis: The first part of the study will involve adapting the UK-based e-Nutri FFQ to reflect dietary habits of Turkish adults (eNutri-Turkey), such as revising the food list, taking portion size photos, and incorporating Turkish food composition data. The revised FFQ delivered online will be validated against three 24-hour recalls by phone (reference method) and the FFQ will be administered twice to assess reproducibility. The study will employ Cronbach's Alpha for internal consistency and the Bland-Altman method for validity. Additionally, inter-rater reliability and reproducibility will be assessed through Cohen's Kappa and ICC analysis, respectively. The eNutri DQS will be adapted in accordance with Turkish dietary guidelines. Following the adaptation, its validity will be assessed using existing Turkish population nutrient data. This analysis will involve retrospectively calculating the DQS and examining its associations with key risk markers of chronic diseases (BMI, blood pressure, blood glucose and cholesterol levels). Additionally, two qualitative studies will be conducted before starting the validation study. Dietitians and nutrition academics from Turkey (n=10) will provide insights on the suitability and effectiveness of eNutri-Turkey through one-to-one interviews. Feedback received will be used to improve the FFQ and DQS.